Cellular and Molecular Physiology Core

项目概要-细胞分子生理学核心 细胞和分子生理学核心是该中心的“工作马”，但它也继续作为 一个创新中心，为肝脏研究人员提供最新的实验模型。核心是 组织向肝脏中心研究者提供技术专业知识、设备和人员， 为他们提供最先进的细胞和分子研究资源， 成本效益的方式。核心在开发用于肝脏研究的新细胞和动物模型方面有着悠久的历史。 目前，核心分为两个部分：（1）细胞分离和细胞培养部分和（2） 分子组成部分。（a）分离的细胞制剂，包括：肝细胞， 胆管细胞、内皮细胞、星状细胞、门静脉成纤维细胞和肝淋巴细胞，主要来自小鼠 还有老鼠当可用时，也使用人肝细胞。超过3，400个分离的细胞被分离。 （B）用于短期和长期培养的细胞培养设施， （c）使用定量RT-PCR和红外成像检测的蛋白质和基因表达;（d）改变 使用siRNA转染、腺病毒感染和 CRISPR技术;（e）提供各种肝病动物模型和（f）疾病特异性小鼠模型 和人肝类器官，来源于iPSC、胆汁和原代肝组织。通过集中这些程序 在核心设施中，成本和工作量大大减少，调查人员得到高度严谨保证， 可重复性和质量控制，并且制剂通常可以由多个人同时使用。 调查员Mario Strazzabosco，医学博士，博士，拥有超过25年的相关经验， 核心与合作的名誉董事，詹姆斯L。博耶，医学博士，谁拥有超过40年的 这些准备工作和程序的工作经验。他们由Romina Fiorotto博士协助， 蔡世英博士，确保日常监督，可用性，并为研究者提供建议，其中许多 服务

PROJECT SUMMARY – CELLULAR MOLECULAR PHYSIOLOGY CORE The Cellular and Molecular Physiology Core is the “work horse” of this Center, but it also continues to serve as an innovation hub to provide liver investigators with the most up-to-date experimental models. The core is organized to provide technical expertise, equipment and personnel to Liver Center Investigators in order to provide them with state of the art cell and molecular research resources in an efficient, quality-controlled and cost-effective manner. The Core has a long history of developing new cell and animal models for liver research. Currently, the Core is divided into two Components: (1) The Cell Isolation and Cell Culture Component and (2) The Molecular Component. These are subdivided into: (a) Isolated cell preparations, including: hepatocytes, cholangiocytes, endothelial cells, stellate cells, portal fibroblasts and hepatic lymphocytes, primarily from mice and rats. Human hepatocytes are also utilized when available. Over 3,400 separate cell isolations were performed during the current award period; (b) Cell culture facilities for short and long-term cultures and cell lines; (c) Protein and gene expression using Quantitative RT-PCR and Infrared imaging detection; (d) Altering gene expression in liver-related cells, cell lines and tissues using siRNA transfection, adenovirus infection, and CRISPR technologies; (e) providing a variety of animal models of liver disease and (f) disease-specific mouse and human liver organoids, derived from iPSC’s, bile, and primary liver tissue. By centralizing these procedures in a Core facility, cost and effort are dramatically reduced, investigators are assured of a high degree of rigor, reproducibility, and quality control, and preparations can often be used simultaneously by more than one investigator. Mario Strazzabosco, MD, PhD, who has more than 25 years of relevant experience, directs this core with the collaboration of the Emeritus Director, James L. Boyer, MD, who has more than 4 decades of experience working with these preparations and procedures. They are assisted by Romina Fiorotto, PhD, and Shi-Ying Cai, PhD, which assures daily supervision, availability, and advice to investigators for many of these services.